What was the key driver behind the Adherium (ASX:ADR) sales update in March 2026?

Adherium reported a significant acceleration in its commercial strategy fueled by the performance of its Hailie Smartinhaler platform and remote patient monitoring services.

How did Adherium (ASX:ADR) perform relative to the previous quarter?

The company’s RPM revenue for January and February 2026 combined reached A$198,000, which has already surpassed the entire Q2 FY26 total of $171,000. With one month remaining in the current quarter, Adherium is on track to post a record quarterly result for its monitoring segment.

The company’s RPM revenue for January and February 2026 combined reached A$198,000, which has already surpassed the entire Q2 FY26 total of A$171,000. With one month remaining in the current quarter, Adherium is on track to post a record quarterly result for its monitoring segment.

Adherium saw cumulative RPM device shipments increase by 43% in the first two months of the 2026 calendar year, reaching a total of 3,071 units. More importantly for revenue, patient activations jumped 53% to 2,183 units.

How do the new 2026 CPT reimbursement codes impact Adherium (ASX:ADR)?

Effective Jan. 1, new CPT (Current Procedural Terminology) codes lowered the thresholds required to bill insurance for patient monitoring. This regulatory change allows Adherium to bill for services earlier and with improved efficiency, acting as a major tailwind for cash flow.

What role does the Adherium Care Team play in the current investment thesis?

The internal Care Team is responsible for driving the conversion of shipped devices into activated patients who generate monthly revenue. Management specifically credited this team’s infrastructure for the 53% surge in activations during early 2026.

What is the significance of the partnership with Allergy Partners?

The collaboration with Allergy Partners provides Adherium access to an estimated 48,000 insurance-verified asthma patients with compatible devices. This partnership significantly expands the company's sales pipeline and validates its commercial model with a large-scale clinical partner.

What are the primary risks for Adherium (ASX:ADR) despite the revenue growth?

Despite the triple-digit percentage growth trends, Adherium remains a high-risk "penny stock" with a share price of approximately $0.0020. The company’s total RPM revenue of A$198,000 over two months is still low in absolute terms relative to the typical operating costs of a listed medtech firm.

Image for illustrative purposes only. Not a real photo.

Adherium revenue jumps 51% on strong RPM momentum

Written by Isaac FrancisPublished Mar 10, 2026, 2:31 AMLast Updated Jul 6, 2026, 10:44 AM

Adherium (ASX:ADR) announced an acceleration in its commercial strategy, driven by the strong performance of its Hailie Smartinhaler platform.

In a quarter-to-date sales update, the company highlighted a substantial 51% increase in remote patient monitoring revenue, climbing from $68,000 in December 2025 to $103,000 in February 2026.

The combined revenue for January and February has already reached $198,000, surpassing the entire previous quarter’s total with one month still remaining.

Cumulative RPM device shipments rose by 43%, reaching 3,071 units, while patient activations saw a 53% jump to 2,183.

Adherium credits this trajectory to its dedicated Care Team and a streamlined billing environment.

The introduction of new CPT reimbursement codes on Jan. 1 has lowered billing thresholds, allowing for earlier and more efficient revenue collection—a move the company describes as a significant "tailwind" for the 2026 calendar year.

Furthermore, Adherium has expanded its scalability through strategic partnerships, including a collaboration with Allergy Partners.

The alliances provide the company access to approximately 48,000 insurance-verified asthma patients with compatible devices.

At the time of reporting, Adherium's share price was $0.0020.

Adherium revenue jumps 51% on strong RPM momentum

Frequently asked questions

Assets related to this article